BioPharmSignal logoBioPharmSignal

Biotech News

ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

ALX Oncology (ALXO)ALX OncologyCompany update

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership

Related news

ALXOALX Oncology2026-08-06 12:00 EST

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALXOALX Oncology2026-06-30 20:40 EST

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

MMSIMerit Medical2026-08-05 16:00 EST

Merit Medical to Participate in Upcoming Investors Conferences in August

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

CHRSCoherus BioSciences, Inc.2026-08-17 21:33 EST

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

KURAKura Oncology2026-08-07 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

IMTXImmatics2026-07-17 14:25 EST

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

View all latest news

ALX Oncology

CD47-Directed Immuno-Oncology ALX Oncology develops therapies intended to activate innate and adaptive antitumor immunity. Its lead approach blocks CD47 signaling while seeking to avoid broad binding to healthy cells. Evorpacept Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other...

Recent company news

ALXOALX Oncology2026-08-06 12:00 EST

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALXOALX Oncology2026-06-30 20:40 EST

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALXOALX Oncology2026-06-30 12:00 EST

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

ALXOALX Oncology2026-06-01 12:00 EST

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

ALXOALX Oncology2026-05-08 12:00 EST

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
2.04 USD
Market cap
239.52M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States